Kiniksa price target raised to $53 from $50 at Wedbush

SelfRugger · 2026-04-04T12:40:50+00:00

Wedbush analyst David Nierengarten increased Kiniksa's price target to $53 from $50, maintaining an Outperform rating. The adjustment follows strong Arcalyst revenue, exceeding estimates and indicating growth in prescriber engagement.

SelfRugger

2026-04-04 12:40:50

Abstract generation in progress

Kiniksa price target raised to $53 from $50 at Wedbush

TipRanks

Thu, February 26, 2026 at 10:29 PM GMT+9 1 min read

In this article:

KNSA

-1.70%

Wedbush analyst David Nierengarten raised the firm’s price target on Kiniksa (KNSA) to $53 from $50 and keeps an Outperform rating on the shares. The firm notes Arcalyst net product revenue of $202.1M in Q4 and $677.6M for FY25 was in line with the pre-announcement and exceeded its prior estimates, reflecting continued expansion in prescriber breadth and depth alongside longer duration of therapy.

Claim 50% Off TipRanks Premium

Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions

Stay ahead of the market with  the latest news and analysis  and maximize your portfolio's potential

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on KNSA:

Disclaimer & DisclosureReport an Issue

Kiniksa reports Q4 EPS 17c, consensus 33c

Shopify, eBay upgraded: Wall Street’s top analyst calls

Kiniksa initiated with a Buy at Canaccord

Kiniksa Pharmaceuticals Reshapes Leadership With New COO, CSO

Kiniksa price target raised to $50 from $48 at Wedbush

Terms and Privacy Policy

Privacy Dashboard

More Info

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.